LA
DMAAR

Linden Advisors’s Drugs Made In America Acquisition Corp Rights DMAAR Stock Holding History

Linden Advisors’s Portfolio DMAAR Stock Details DMAAR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$97.8K Hold
850,000
– – ﹤0.01% 544
2026
Q1 		$48.9K Hold
850,000
– – ﹤0.01% 508
2025
Q4 		$148K Hold
850,000
– – ﹤0.01% 380
2025
Q3 		$175K Buy
+850,000
New +$158K ﹤0.01% 326

Other funds holding DMAAR

PAMP
Polar Asset Management Partners Toronto, Ontario, Canada $6.07B AUM 34.81% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Toronto Dominion Bank
Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $86.4B AUM 59.51% 1-Year Est. Return
Hudson Bay Capital Management
Hudson Bay Capital Management Stamford, Connecticut $36.8B AUM 42.13% 1-Year Est. Return
CS
Clear Street New York $39.5B AUM 124.03% 1-Year Est. Return
HCM
Highbridge Capital Management New York $4.11B AUM 26.03% 1-Year Est. Return
RCM
Rivernorth Capital Management West Palm Beach, Florida $2.1B AUM 2.15% 1-Year Est. Return
BFM
Boothbay Fund Management New York $7.6B AUM 109.3% 1-Year Est. Return
AGM
Alpine Global Management New York $615M AUM 34.28% 1-Year Est. Return
LP
LMR Partners London, United Kingdom $26.8B AUM 68.38% 1-Year Est. Return

Linden Advisors's DMAAR Position: Q2 2026 in Review

Linden Advisors held its Drugs Made In America Acquisition Corp Rights (DMAAR) position steady in Q2 2026 at 850,000 shares worth $97.8K. The position accounts for ﹤0.01% of the portfolio, ranked #544.

Linden Advisors first reported a position in DMAAR in Q3 2025 and has held it in 4 quarters since. The position peaked at $175K in Q3 2025. 28 funds tracked by Wall St. Rank hold DMAAR as of Q2 2026.

  • Linden Advisors held 850,000 shares of Drugs Made In America Acquisition Corp Rights worth $97.8K as of Q2 2026.
  • Linden Advisors left its Drugs Made In America Acquisition Corp Rights share count unchanged in Q2 2026.
  • Drugs Made In America Acquisition Corp Rights made up ﹤0.01% of Linden Advisors's portfolio in Q2 2026, its #544 holding.
  • Linden Advisors first reported a position in Drugs Made In America Acquisition Corp Rights in Q3 2025 and has held it in 4 quarters since.
  • Linden Advisors's Drugs Made In America Acquisition Corp Rights position peaked at $175K in Q3 2025.
  • 28 funds tracked by Wall St. Rank held Drugs Made In America Acquisition Corp Rights as of Q2 2026.

Based on Linden Advisors's 13F filing for Q2 2026, filed 14 Aug 2026.